# Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis

> **NCT02895100** · PHASE2 · TERMINATED · sponsor: **Protagonist Therapeutics, Inc.** · enrollment: 98 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** PTG-100
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02895100
- **Lead sponsor:** Protagonist Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12
- **Primary completion:** 2018-03-26
- **Final completion:** 2018-03-26
- **Target enrollment:** 98 (ACTUAL)
- **Why stopped:** Data Monitoring Committee discontinued the trial due to futility-based outcome
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02895100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02895100, "Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02895100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*